Netvax
adjuvanted vaccine against necrotic enteritis of chickens due to Clostridium perfringens
Table of contents
Overview
The marketing authorisation for Netvax has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Netvax
|
| Agency product number |
EMEA/V/C/000134
|
| Active substance |
Clostridium-perfringens-type-A alpha toxoid
|
| International non-proprietary name (INN) or common name |
adjuvanted vaccine against necrotic enteritis of chickens due to Clostridium perfringens
|
| Species |
Chicken
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI01AB08
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Intervet International BV
|
| Revision |
2
|
| Date of issue of marketing authorisation valid throughout the European Union |
16/04/2009
|
| Contact address |
Intervet International B.V.
Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands |
Product information
19/09/2013 Netvax - EMEA/V/C/000134 - IB/0006
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for aves
Therapeutic indication
For the active immunisation of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period.
To reduce mortality and the incidence and severity of lesions caused by Clostridium-perfringens-type-A-induced necrotic enteritis. Efficacy was demonstrated by challenge of chicks approximately three weeks after hatching.
The onset of passive transfer of immunity: 6 weeks following completion of the vaccination procedure.
The duration of passive transfer of immunity: 51 weeks following completion of the vaccination procedure.